Retinal Vein Occlusion Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Retinal Vein Occlusion pipeline constitutes 15+ key companies continuously working towards developing 15+ Retinal Vein Occlusion treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Retinal Vein Occlusion Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinal Vein Occlusion Market.

The Retinal Vein Occlusion Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Retinal Vein Occlusion Pipeline Report: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Retinal Vein Occlusion treatment therapies with a considerable amount of success over the years.
• Retinal Vein Occlusion companies working in the treatment market are Kalaris Therapeutics, Annexin Pharmaceuticals AB, Merck, tedromer Kodiak sciences, Sunshine Guojian Pharmaceutical, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer, Aerpio Therapeutics, The Emmes Company, LLC, Regeneron Pharma, Hoffmann-La Roche, and others, are developing therapies for the Retinal Vein Occlusion treatment
• Emerging Retinal Vein Occlusion therapies in the different phases of clinical trials are- TH103, ANXV, MK-8748, Tarcocimab, 601 RVO, TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), ranibizumab, dexamethasone implant, AKB-9778, bevacizumab, Aflibercept, pegaptanib sodium (Macugen), TLC399 (ProDex), Faricimab, GB-102, and others are expected to have a significant impact on the Retinal Vein Occlusion market in the coming years.
• In October 2025, According to data presented at Eyecelerator 2025 in Orlando, Florida, Patients in the phase I/IIa RIOJA trial evaluating Tiespectus (MK-8748) for macular edema secondary to branch retinal vein occlusion (BRVO) demonstrated a mean gain of 16.7 letters in best-corrected visual acuity (BCVA) and a mean central subfield thickness(CST) reduction of 157.8 μm at 12 weeks.
• In August 2025, Annexin Pharmaceuticals had received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase IIa clinical trial with the drug candidate ANXV for the treatment of diabetic retinopathy (DR). As part of the preparations for a future Phase IIb trial, patients with newly diagnosed retinal vein occlusion (RVO) will also be included.

Retinal Vein Occlusion Overview
Retinal Vein Occlusion (RVO) is a common vascular disorder of the retina, caused by blockage of the retinal veins, leading to impaired blood flow. This results in fluid leakage, retinal swelling (macular edema), and reduced oxygen supply to retinal tissues, which can cause vision loss or blindness if untreated. RVO is typically classified into Central Retinal Vein Occlusion (CRVO), affecting the main retinal vein, and Branch Retinal Vein Occlusion (BRVO), affecting smaller branch veins. Risk factors include hypertension, diabetes, glaucoma, and advanced age. Early diagnosis and treatments like anti-VEGF therapy, corticosteroids, or laser therapy can help manage symptoms and prevent vision deterioration.

Get a Free Sample PDF Report to know more about Retinal Vein Occlusion Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Retinal Vein Occlusion Drugs Under Different Phases of Clinical Development Include:
• TH103: Kalaris Therapeutics
• ANXV: Annexin Pharmaceuticals AB
• MK-8748: Merck
• Tarcocimab: tedromer Kodiak sciences
• 601 RVO: Sunshine Guojian Pharmaceutical
• TLC399: Taiwan Liposome Company
• AR-1105: Aerie Pharmaceuticals
• GB-102: Graybug Vision
• ONS-5010 (Lytenava): Outlook Therapeutics
• KSI-301: Kodiak Sciences
• Vabysmo (faricimab): Roche/Chugai Pharmaceuticals
• ranibizumab: Novartis
• dexamethasone implant: Allergan
• pegaptanib sodium: Pfizer
• AKB-9778: Aerpio Therapeutics
• bevacizumab: The Emmes Company, LLC
• Aflibercept: Regeneron Pharma
• pegaptanib sodium (Macugen): Pfizer
• TLC399 (ProDex): Taiwan Liposome Company
• Faricimab: Hoffmann-La Roche
• GB-102: Graybug Vision

Retinal Vein Occlusion Route of Administration
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Retinal Vein Occlusion Molecule Type
Retinal Vein Occlusion Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Retinal Vein Occlusion Pipeline Therapeutics Assessment
• Retinal Vein Occlusion Assessment by Product Type
• Retinal Vein Occlusion By Stage and Product Type
• Retinal Vein Occlusion Assessment by Route of Administration
• Retinal Vein Occlusion By Stage and Route of Administration
• Retinal Vein Occlusion Assessment by Molecule Type
• Retinal Vein Occlusion by Stage and Molecule Type

DelveInsight's Retinal Vein Occlusion Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Retinal Vein Occlusion product details are provided in the report. Download the Retinal Vein Occlusion pipeline report to learn more about the emerging Retinal Vein Occlusion therapies at:
https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Retinal Vein Occlusion Therapeutics Market include:
Key companies developing therapies for Retinal Vein Occlusion are - Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.


Retinal Vein Occlusion Pipeline Analysis:
The Retinal Vein Occlusion pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
• Retinal Vein Occlusion key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Retinal Vein Occlusion drugs and therapies-
https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Retinal Vein Occlusion Pipeline Market Drivers
• Rising prevalence of RVO due to aging populations and increasing incidence of diabetes and hypertension.
• Advancements in novel therapies such as anti-VEGF agents, gene therapies, and sustained-release drug delivery systems.
• Growing awareness and early diagnosis improving treatment uptake.
• Increasing investments by biopharma in RVO-focused clinical trials and pipeline development.
• Expansion of healthcare infrastructure in emerging markets facilitating access to innovative therapies.

Retinal Vein Occlusion Pipeline Market Barriers
• High cost of advanced therapies limiting patient access.
• Challenges in achieving long-term efficacy and safety in novel treatments.
• Regulatory hurdles and lengthy approval timelines for new pipeline drugs.
• Variability in patient response and difficulty in treating severe or chronic RVO cases.
• Limited awareness and diagnostic capabilities in low-resource regions, delaying early intervention.

Scope of Retinal Vein Occlusion Pipeline Drug Insight
• Coverage: Global
• Key Retinal Vein Occlusion Companies: Kalaris Therapeutics, Annexin Pharmaceuticals AB, Merck, tedromer Kodiak sciences, Sunshine Guojian Pharmaceutical, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer, Aerpio Therapeutics, The Emmes Company, LLC, Regeneron Pharma, Hoffmann-La Roche, and others
• Key Retinal Vein Occlusion Therapies: TH103, ANXV, MK-8748, Tarcocimab, 601 RVO, TLC399, AR-1105, GB-102, ONS-5010 (Lytenava), KSI-301, Vabysmo (faricimab), ranibizumab, dexamethasone implant, AKB-9778, bevacizumab, Aflibercept, pegaptanib sodium (Macugen), TLC399 (ProDex), Faricimab, GB-102, and others
• Retinal Vein Occlusion Therapeutic Assessment: Retinal Vein Occlusion current marketed and Retinal Vein Occlusion emerging therapies
• Retinal Vein Occlusion Market Dynamics: Retinal Vein Occlusion market drivers and Retinal Vein Occlusion market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-servicesa

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.